title: Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial.
abstract: Objectives. To evaluate the efficacy, safety, and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9-month followup period. Design. Randomized clinical trial. Place. "Eusebio Hernández" Hospital, Havana, Cuba. Subjects. 220 women with symptomatic uterine fibroids. Treatment. One-half (2.5 mg) or one-whole 5 mg mifepristone tablet. Variables to Evaluate Efficacy. Changes in fibroid and uterine volumes, in symptomatic prevalence and intensity, and in quality of life. Results. After 3-month treatment, fibroid volume decreased by 27.9% (CI 95% 20-35) and 45.5% (CI 95% 37-62), in the 2.5 and 5 mg groups, respectively, P = 0.003. There was no difference in the prevalence of symptoms at the end of treatment, unlike after 6- and 9-month followup when there was a difference. Amenorrhea was significantly higher in the 5 mg group, P = 0.001. There were no significant differences in mifepristone side effects between the groups. Both groups displayed a similar improvement in quality of life. Conclusions. The 2.5 mg dosage resulted in a lesser reduction in fibroid size but a similar improvement in quality of life when compared to the 5 mg dose. This trial is registered with ClinicalTrials.gov NCT01786226.
authors: Mediterránea Médica Clinic, C/Salvador Guinot 14, 46017 Valencia, Spain.
authors: Josep Lluis
authors: JL
authors: Carbonell
authors: Rita
authors: R
authors: Acosta
authors: Yasmirian
authors: Y
authors: Pérez
authors: Roberto
authors: R
authors: Garcés
authors: Carlos
authors: C
authors: Sánchez
authors: Giuseppe
authors: G
authors: Tomasi
references: Eur J Obstet Gynecol Reprod Biol. 2012 Apr;161(2):202-8
references: 22269473
references: Obstet Gynecol. 2003 Feb;101(2):243-50
references: 12576246
references: Obstet Gynecol. 2002 Feb;99(2):290-300
references: 11814511
references: Hum Reprod. 2009 Aug;24(8):1870-9
references: 19389793
references: Int J Gynaecol Obstet. 2010 May;109(2):121-4
references: 20132932
references: Obstet Gynecol. 2006 Dec;108(6):1381-7
references: 17138770
references: Hum Pathol. 2011 Jul;42(7):947-53
references: 21315422
references: Mod Pathol. 2008 May;21(5):591-8
references: 18246050
references: Int J Womens Health. 2013 Mar 19;5:115-24
references: 23658500
references: Hum Reprod Update. 2007 Nov-Dec;13(6):567-80
references: 17630398
references: Fertil Steril. 2011 Feb;95(2):767-72.e1-2
references: 21055739
references: Obstet Gynecol. 2004 Jun;103(6):1331-6
references: 15172874
references: J Minim Invasive Gynecol. 2005 May-Jun;12(3):227-33
references: 15922980
references: Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):215-8
references: 19586708
references: Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):77-83
references: 19281585
references: Contraception. 2010 Nov;82(5):442-52
references: 20933118
references: Int J Womens Health. 2012;4:75-84
references: 22448109
references: Hum Reprod Update. 2005 May-Jun;11(3):293-307
references: 15790602
references: Obstet Gynecol. 2008 May;111(5):1129-36
references: 18448745
references: Obstet Gynecol. 2008 Nov;112(5):1029-36
references: 18978102